Aurobindo Pharma has announced the strategic transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited. Executed via a slump sale, this restructuring aims to streamline operations and accelerate the growth of the company’s domestic footprint. The business transfer, valued at INR 143.21 Crores, is expected to be completed within 90 to 120 days, following the fulfillment of standard closing conditions.
Restructuring for Operational Efficiency
In a move to drive sharper focus on its domestic market, Aurobindo Pharma is consolidating its branded generic formulations business under Auropharm Limited (formerly Auro Pharma Limited). This reorganization is intended to leverage the subsidiary’s existing infrastructure, including its current operations handling non-oncology formulations previously acquired from Khandelwal Laboratories Limited. By centralizing these assets, the company aims to achieve greater operational efficiency and faster growth in India.
Transaction Details and Financial Impact
The transaction, approved by the Board of Directors on April 6, 2026, is structured as a slump sale. Auropharm Limited will acquire all related assets and liabilities, including intellectual property, licenses, contracts, and inventory. The lumpsum consideration for the business transfer is INR 143.21 Crores.
For the financial year ended March 31, 2025, the domestic branded generic formulations business recorded a standalone revenue of Rs. 1,753.40 million, which represented 0.55% of the company’s total consolidated turnover. Additionally, the transferred business accounted for Rs. 1,481.40 million in net worth, or 0.45% of the consolidated net worth of the parent entity.
Strategic Outlook
The consolidation does not result in any change to the shareholding pattern of the parent company, as the transaction is strictly between a holding company and its wholly owned subsidiary. Post-completion, the financial accounts of Auropharm Limited will continue to be consolidated with those of the parent entity, ensuring no impact on the overall consolidated financial position of the group.
Source: BSE
